Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence
Year: 2021
Type: article
Study design: Clinical Trial
Abstract: BACKGROUND: Opioid agonist treatment (OAT) is an effective intervention for opioid dependence. Extended-release buprenorphine injections (BUP-XR) may have additional potential benefits over sublingual buprenorphine. This single-arm trial evaluated outcomes among people receiving 48 weeks of BUP-XR in diverse community healthcare settings in Australia, permitting examination of outcomes when BUP-XR is delivered in standard practice. METHODS: Participants were recruited from a network of specialist public drug treatment services, primary care and some private practices in three states. Following a minimum 7 days on 8-32 mg of sublingual buprenorphine (±naloxone), participants received monthly subcutaneous BUP-XR injections administered by a healthcare practitioner and completed monthly research interviews. The primary endpoint was retention in treatment at 48 weeks. FINDINGS: Participants (n = 100) were 28% women, mean age 44 years with a long history of OAT (median 5.8 years); heroin was the most common opioid of concern (58%). Treatment retention at 24 and 48 weeks was 86% and 75%, respectively. Participants with past-month injecting drug use (OR 0.23; 95%CI: 0.09-0.61) or heroin use (OR 0.23; 95%CI: 0.08-0.65) at baseline had lower odds of being retained in treatment to 48 weeks. Reductions in multiple forms of extra-medical drug use were observed. Improvements in quality of life, participation in employment, and treatment satisfaction measures were also observed. INTERPRETATION: This real-world implementation study of BUP-XR demonstrated high retention and treatment satisfaction. This study provides important additional data on the uptake and experience of clients, with relevance for policy makers, health service planners, administrators, and practitioners. FUNDING: Indivior. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03809143.
Authors: Michael Farrell, Jeyran Shahbazi, Marianne Byrne, Jason Grebely, Nicholas Lintzeris, Mark Chambers, Briony Larance, Robert Ali, Suzanne Nielsen, Adrian Dunlop, Gregory J. Dore, Michael McDonough, Mark Montebello, Thomas Nicholas, Rob Weiss, Craig Rodgers, Jon Cook, Louisa Degenhardt
Institutions: UNSW Sydney, National Drug and Alcohol Research Centre, Kirby Institute, The University of Sydney, South Eastern Sydney Local Health District, University of Wollongong, Illawarra Health and Medical Research Institute, The University of Adelaide, Eastern Health, Monash University, Hunter Medical Research Institute, Hunter New England Local Health District, University of Newcastle Australia, Northern Sydney Local Health District, Frankston Hospital, Government of New South Wales, Western Health
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,740
OpenAlex ID: W3209055400
